Literature DB >> 28598789

CROI 2017: HIV Epidemic Trends and Advances in Prevention.

Albert Y Liu1, Susan P Buchbinder1.   

Abstract

At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), trends in the HIV epidemic were highlighted, with decreasing HIV incidence reported across several countries, although key groups remain underdiagnosed and undertreated. In the United States, men who have sex with men (MSM) continue to comprise the largest number of new and undiagnosed HIV infections, with rising incidence in MSM 25 to 34 years old and Latino MSM. Phylogenetics are being used to identify rapidly growing HIV transmission clusters, which can inform prevention efforts. HIV testing is a crucial first step for accessing HIV prevention and treatment, and several innovative strategies to increase HIV testing show promise. Sexually transmitted infections (STIs) have been on the rise but predate widespread use of HIV preexposure prophylaxis (PrEP); enhanced STI screening and treatment coupled with PrEP could substantially reduce STI incidence in the United States. Several studies indicate increasing PrEP awareness and use, although disparities exist in vulnerable populations. PrEP persistence remains a challenge, and practitioner adherence to prescribing guidelines is suboptimal. Novel PrEP delivery models are being developed to increase PrEP knowledge, access, and support.

Entities:  

Mesh:

Year:  2017        PMID: 28598789      PMCID: PMC5677042     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  5 in total

1.  Pre-exposure prophylaxis failure with tenofovir disoproxil.

Authors:  Hendrik Streeck; Jens Verheyen; Julian Storim; Ulf Dittmer; Christoph Jochum; Jörg Timm; Stefan Esser
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

2.  Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Authors:  David C Knox; Peter L Anderson; P Richard Harrigan; Darrell H S Tan
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

3.  The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.

Authors:  Michael Martin; Suphak Vanichseni; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Marcel E Curlin; Supawadee Na-Pompet; Anchalee Warapronmongkholkul; Somyot Kittimunkong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Kachit Choopanya
Journal:  AIDS       Date:  2015-04-24       Impact factor: 4.177

4.  Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States.

Authors:  Dawn K Smith; Sherri L Pals; Jeffrey H Herbst; Sanjyot Shinde; James W Carey
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

5.  Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.

Authors:  Julie Fox; Michael Brady; Hannah Alexander; Olubanke Davies; Nicola Robinson; Mathew Pace; Laura Else; John Cason; Saye Khoo; David Back; Sarah Fidler; John Frater
Journal:  Infect Dis Ther       Date:  2016-01-09
  5 in total
  3 in total

1.  STD Partner Services to Monitor and Promote HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men.

Authors:  David A Katz; Julia C Dombrowski; Michael Barry; Dawn Spellman; Teal R Bell; Matthew R Golden
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

Review 2.  Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.

Authors:  Bluma G Brenner; Ruxandra-Ilinca Ibanescu; Isabelle Hardy; Michel Roger
Journal:  Viruses       Date:  2017-12-28       Impact factor: 5.048

Review 3.  Pharmacy-Based Interventions to Increase Use of HIV Pre-exposure Prophylaxis in the United States: A Scoping Review.

Authors:  Alice Zhao; Derek T Dangerfield; Amy Nunn; Rupa Patel; Jason E Farley; Chinenye C Ugoji; Lorraine T Dean
Journal:  AIDS Behav       Date:  2021-10-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.